293 cells were transfected with anti-MSLN-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Mesothelin (296-580), Fc Tag (Cat. No. MSN-HF25x, 0.3 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-MSLN-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Mesothelin (296-580), Fc Tag (Cat. No. MSN-HF25x).
can bind Human MS4A1 / CD20 Full Length Protein, His Tag (Cat. No. CD0-H55Ha)with an affinity constant of 1.21 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Anti-human MSLN MAb (chimeric mouse-human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface, can bind GFP Fusion Human Mesothelin (296-580), His Tag (Cat. No. MSN-HG2P4) with an affinity constant of 0.542 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| iCasp9M28z | iCasp9M28z | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Mesothelioma; Breast Neoplasms; Lung Neoplasms; Neoplasm Metastasis | Details |
| LMB-100 | LMB-100; RG-7787; RO-6927005 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Neoplasms; Mesothelioma | Details |
| ATA-2271 | ATA-2271 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Atara Biotherapeutics | Mesothelioma | Details |
| MCY-M11 | MCY-M11 | Phase 1 Clinical | Maxcyte | Ovarian Neoplasms; Mesothelioma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma | Details |
| BMS-986148 | BMS-986148 | Phase 2 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| RNA-Meso-CIR-T | RNA-Meso-CIR-T | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Mesothelioma | Details |
| Anetumab ravtansine | BAY-94-9343; BAY-94-9343-SPDB-DM4; Anti-mesothelin antibody-drug conjugate BAY 94-9343 | Phase 2 Clinical | Bayer Ag, Morphosys | Ovarian Neoplasms; Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| Amatuximab | MORAb-009; MORAB-009-006 | Phase 2 Clinical | National Cancer Institute | Ovarian Neoplasms; Neoplasms; Pancreatic Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
| KD-021 (Nanjing KAEDI Biotech) | KD-021 | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Neoplasms | Details |
| Anti-mesothelin CAR-T (Pregene) | Clinical | Pregene (Shenzhen) Biotechnology Co Ltd | Hydrothorax | Details | |
| Anti-mesothelin CAR-T (Legend) | Phase 1 Clinical | Ovarian Neoplasms | Details | ||
| Autologous Mesothelin-specific TCR-T Cell Therapy (Lonza Walkersville) | Details | ||||
| anti-mesothelin thorium-227 labeled antibody chelator conjugate | BAY-2287411 | Phase 1 Clinical | Bayer Ag | Ovarian Neoplasms; Mesothelioma | Details |
This web search service is supported by Google Inc.
A-Z
